Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
219 hedge funds and large institutions have $541M invested in Sorrento Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 79 increasing their positions, 43 reducing their positions, and 42 closing their positions.
89% more call options, than puts
Call options by funds: $90.3M | Put options by funds: $47.9M
84% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 43
29% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 42
5% more funds holding
Funds holding: 209 → 219 (+10)
33% less capital invested
Capital invested by funds: $805M → $541M (-$264M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.76M |
| 4 |
JP Morgan Chase
New York
|
+$6.62M |
| 5 |
Goldman Sachs
New York
|
+$5.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12M |
| 2 |
Morgan Stanley
New York
|
-$6.38M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.87M |
| 4 |
Millennium Management
New York
|
-$4.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.51M |
SRNE Hedge Fund Activity: Q4 2020 in Review
219 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2020, worth a combined $541M — down 33% from $805M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new SRNE positions and 42 closed out — a net gain of 12 holders — while 79 added to existing stakes and 43 trimmed.
The largest buyer was BlackRock, adding an estimated $20.9M. The largest seller was Cormorant Asset Management, cutting an estimated $12M.
- 219 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2020, up from 209 in Q3 2020.
- Funds reported $541M of Sorrento Therapeutics, Inc. stock for Q4 2020, down 33% quarter-over-quarter.
- 54 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2020 and 42 closed out, a net change of +12 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2020 was BlackRock, an estimated $20.9M added.
- The largest Sorrento Therapeutics, Inc. seller in Q4 2020 was Cormorant Asset Management, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2020.